Vaccine strategies for human papillomavirus-associated cancers

Anna S. Kadish, Mark H. Einstein

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Purpose of review: To review novel immunologic strategies for the prevention and treatment of human papillomavirus infection and associated diseases. Both animal model systems and human protocols are discussed. Recent findings: Many vaccine platforms for both prevention of human papillomavirus infection and treatment of associated disease have been developed. Virus-like particle constructs containing human papillomavirus capsid proteins have been shown to protect against human papillomavirus infection. Novel peptide or protein constructs containing modified E6 or E7 proteins, novel adjuvants, fusion proteins such as immunoglobulin-G-heavy chain E7, or heat shock proteins have been made as therapeutic modalities. In addition, many new recombinant vaccine vectors such as vaccinia, Listeria species, adenovirus, Semliki Forest vectors, and others have been developed as carriers of immunotherapeutic agents. Recently, chimeric virus-like particle vaccines have been developed to treat existing human papillomavirus-induced neoplasms. Summary: Immunotherapy protocols using a variety of recombinant vectors and modified human papillomavirus proteins induce in-vitro T cell responses and may lead to tumor regression. Vaccine-induced in-vitro immune reactivity and clinical vaccine effects are often not well associated. Further analysis of ongoing human immunotherapy trials is awaited.

Original languageEnglish (US)
Pages (from-to)456-461
Number of pages6
JournalCurrent Opinion in Oncology
Volume17
Issue number5
DOIs
StatePublished - Sep 2005

Fingerprint

Papillomavirus Vaccines
Papillomavirus Infections
Neoplasms
Vaccines
Immunotherapy
Proteins
Virus-Like Particle Vaccines
Vaccinia
Immunoglobulin Heavy Chains
Synthetic Vaccines
Listeria
Capsid Proteins
Heat-Shock Proteins
Adenoviridae
Virion
Therapeutics
Animal Models
Immunoglobulin G
T-Lymphocytes
Peptides

Keywords

  • Adjuvants
  • Adoptive immunotherapy
  • Anal intraepithelial neoplasia
  • Cervical intraepithelial neoplasia
  • Chimeric virus-like particle
  • Fusion proteins
  • Recurrent respiratory papillomatosis
  • Virus-like particle

ASJC Scopus subject areas

  • Cancer Research

Cite this

Vaccine strategies for human papillomavirus-associated cancers. / Kadish, Anna S.; Einstein, Mark H.

In: Current Opinion in Oncology, Vol. 17, No. 5, 09.2005, p. 456-461.

Research output: Contribution to journalArticle

Kadish, Anna S. ; Einstein, Mark H. / Vaccine strategies for human papillomavirus-associated cancers. In: Current Opinion in Oncology. 2005 ; Vol. 17, No. 5. pp. 456-461.
@article{79dc5df0b98245b69e62a72504004de9,
title = "Vaccine strategies for human papillomavirus-associated cancers",
abstract = "Purpose of review: To review novel immunologic strategies for the prevention and treatment of human papillomavirus infection and associated diseases. Both animal model systems and human protocols are discussed. Recent findings: Many vaccine platforms for both prevention of human papillomavirus infection and treatment of associated disease have been developed. Virus-like particle constructs containing human papillomavirus capsid proteins have been shown to protect against human papillomavirus infection. Novel peptide or protein constructs containing modified E6 or E7 proteins, novel adjuvants, fusion proteins such as immunoglobulin-G-heavy chain E7, or heat shock proteins have been made as therapeutic modalities. In addition, many new recombinant vaccine vectors such as vaccinia, Listeria species, adenovirus, Semliki Forest vectors, and others have been developed as carriers of immunotherapeutic agents. Recently, chimeric virus-like particle vaccines have been developed to treat existing human papillomavirus-induced neoplasms. Summary: Immunotherapy protocols using a variety of recombinant vectors and modified human papillomavirus proteins induce in-vitro T cell responses and may lead to tumor regression. Vaccine-induced in-vitro immune reactivity and clinical vaccine effects are often not well associated. Further analysis of ongoing human immunotherapy trials is awaited.",
keywords = "Adjuvants, Adoptive immunotherapy, Anal intraepithelial neoplasia, Cervical intraepithelial neoplasia, Chimeric virus-like particle, Fusion proteins, Recurrent respiratory papillomatosis, Virus-like particle",
author = "Kadish, {Anna S.} and Einstein, {Mark H.}",
year = "2005",
month = "9",
doi = "10.1097/01.cco.0000174038.92526.29",
language = "English (US)",
volume = "17",
pages = "456--461",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Vaccine strategies for human papillomavirus-associated cancers

AU - Kadish, Anna S.

AU - Einstein, Mark H.

PY - 2005/9

Y1 - 2005/9

N2 - Purpose of review: To review novel immunologic strategies for the prevention and treatment of human papillomavirus infection and associated diseases. Both animal model systems and human protocols are discussed. Recent findings: Many vaccine platforms for both prevention of human papillomavirus infection and treatment of associated disease have been developed. Virus-like particle constructs containing human papillomavirus capsid proteins have been shown to protect against human papillomavirus infection. Novel peptide or protein constructs containing modified E6 or E7 proteins, novel adjuvants, fusion proteins such as immunoglobulin-G-heavy chain E7, or heat shock proteins have been made as therapeutic modalities. In addition, many new recombinant vaccine vectors such as vaccinia, Listeria species, adenovirus, Semliki Forest vectors, and others have been developed as carriers of immunotherapeutic agents. Recently, chimeric virus-like particle vaccines have been developed to treat existing human papillomavirus-induced neoplasms. Summary: Immunotherapy protocols using a variety of recombinant vectors and modified human papillomavirus proteins induce in-vitro T cell responses and may lead to tumor regression. Vaccine-induced in-vitro immune reactivity and clinical vaccine effects are often not well associated. Further analysis of ongoing human immunotherapy trials is awaited.

AB - Purpose of review: To review novel immunologic strategies for the prevention and treatment of human papillomavirus infection and associated diseases. Both animal model systems and human protocols are discussed. Recent findings: Many vaccine platforms for both prevention of human papillomavirus infection and treatment of associated disease have been developed. Virus-like particle constructs containing human papillomavirus capsid proteins have been shown to protect against human papillomavirus infection. Novel peptide or protein constructs containing modified E6 or E7 proteins, novel adjuvants, fusion proteins such as immunoglobulin-G-heavy chain E7, or heat shock proteins have been made as therapeutic modalities. In addition, many new recombinant vaccine vectors such as vaccinia, Listeria species, adenovirus, Semliki Forest vectors, and others have been developed as carriers of immunotherapeutic agents. Recently, chimeric virus-like particle vaccines have been developed to treat existing human papillomavirus-induced neoplasms. Summary: Immunotherapy protocols using a variety of recombinant vectors and modified human papillomavirus proteins induce in-vitro T cell responses and may lead to tumor regression. Vaccine-induced in-vitro immune reactivity and clinical vaccine effects are often not well associated. Further analysis of ongoing human immunotherapy trials is awaited.

KW - Adjuvants

KW - Adoptive immunotherapy

KW - Anal intraepithelial neoplasia

KW - Cervical intraepithelial neoplasia

KW - Chimeric virus-like particle

KW - Fusion proteins

KW - Recurrent respiratory papillomatosis

KW - Virus-like particle

UR - http://www.scopus.com/inward/record.url?scp=24044553957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24044553957&partnerID=8YFLogxK

U2 - 10.1097/01.cco.0000174038.92526.29

DO - 10.1097/01.cco.0000174038.92526.29

M3 - Article

VL - 17

SP - 456

EP - 461

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 5

ER -